Clinical Data QurAlis’ Phase 2 data bolster case for genetic approach to sporadic ALS BioSpaceBiogen's Qalsody won FDA approval in 2023 to treat a rare, genetic form of amyotrophic lateral sclerosis.NeuroscienceRead full story pharminent May 5, 2026 (Last updated: May 5, 2026) BioSpace Biogen’s Qalsody won FDA approval in 2023 to treat a rare, genetic form of amyotrophic lateral sclerosis. Neuroscience Read full story Post navigation Previous: Pfizer stays the course for 2026 guidance, dulling impact of Q1 earnings beatNext: Viridian data lift prospects for thyroid eye disease drug Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026